A New Era for Cholangiocarcinoma Therapy – Targeting Metabolic Enzymes
Journal of Clinical and Medical Reviews · 2024
DOI: 10.58489/2836-2330/016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Medical Reviews, 2024. Verfasst von Antonis G. Tsamaloukas.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a malignancy of the biliary tract epithelium and is the second most common primary liver tumor following hepatocellular carcinoma (HCC): it accounts for ~15% of primary liver cancers and ~3% of gastrointestinal malignancies. Due to late diagnoses, poor prognoses, and limited treatment strategies, CCA shows a dismal outcome with a less than 5% overall 5-year survival and only a median overall survival of ~7months. Moreover, epidemiological data show that the incidence (0.3–6 per 100,000) and mortality (1 -6 per 100,000) of CCA is increasing globally over recent decades. Cholangiocarcinoma (CCA) is associated with approximately 3,500 new cases, the second most common primary liver tumor in Germany. Cholangiocarcinoma (CCA) is classified into anatomic subtypes including intrahepatic CCA (iCCA), perihilar CCA (pCCA) and extrahepatic CCA (eCCA).
Zitieren
APA
Tsamaloukas, A. G. (2024). A New Era for Cholangiocarcinoma Therapy – Targeting Metabolic Enzymes. Journal of Clinical and Medical Reviews. https://doi.org/10.58489/2836-2330/016
Vancouver
Tsamaloukas AG. A New Era for Cholangiocarcinoma Therapy – Targeting Metabolic Enzymes. Journal of Clinical and Medical Reviews. 2024. doi:10.58489/2836-2330/016
BibTeX
@article{Tsamaloukas2024,
author = {Tsamaloukas, Antonis G.},
title = {A New Era for Cholangiocarcinoma Therapy – Targeting Metabolic Enzymes},
journal = {Journal of Clinical and Medical Reviews},
year = {2024},
doi = {10.58489/2836-2330/016}
}
EUVIMED